In the first half of 2025, King Faisal Specialist Hospital and Research Centre (KFSH) accounted for nearly half of all clinical trials registered in Saudi Arabia, underscoring its pivotal role in advancing clinical research and healthcare innovation. Supported by a robust team of investigators, research nurses, pharmacists, coordinators, data specialists, and regulatory and ethics experts, KFSH is well-equipped to manage clinical studies from the initial planning stages through patient recruitment, trial execution, and data management.
Since establishing its centralized Clinical Trials service in 2020, KFSH has streamlined research efforts by coordinating various aspects such as feasibility assessments, study activation, trial operations, and regulatory compliance. In the first six months of 2025, the hospital managed 104 active clinical trials and initiated 80 new studies across diverse medical fields including oncology, cardiovascular diseases, autoimmune and musculoskeletal disorders, dermatology, gastroenterology, liver ailments, and endocrine and metabolic issues. This extensive range of studies not only offers patients with complex conditions access to cutting-edge treatments but also generates valuable clinical evidence to address healthcare needs in Saudi Arabia.
A significant milestone for KFSH was the initiation of a Phase I clinical trial treating the first patient with locally manufactured genetically engineered CAR-T cells for relapsed acute lymphoblastic leukemia. This trial is a testament to the integration of local scientific expertise, advanced biomanufacturing, and specialized clinical care within a unified research framework, marking a significant advancement in cell therapy research.
KFSH’s clinical-trial infrastructure also facilitates its involvement in complex international studies, fostering collaboration with global research partners while maintaining stringent standards for patient safety, ethics, data quality, and regulatory adherence. This global engagement will be highlighted at the upcoming C3 US NYC Davos of Healthcare Summit 2026 in New York City on September 14, where KFSH will showcase its approach to clinical research and healthcare innovation.
Recognized among the leading academic medical centers worldwide and in the Middle East, KFSH continues to enhance its reputation through its innovative healthcare solutions and contributions to international hospital rankings. Its commitment to research and development solidifies its standing as a cornerstone of medical advancement in the region.
Legal Disclaimer:
The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.
